前列腺特异性启动子在慢病毒介导基因治疗中的研究进展  

Progress in prostate-specific promoters in lentiviral-mediated gene therapy

作　　者：魏绪磐 杨波 李文娟 张发 梁梦天 吕海迪 周逢海 Wei Xupan;Yang Bo;Li Wenjuan;Zhang Fa;Liang Mengtian;Lv Haidi;Zhou Fenghai(Department of Clinical Medicine,Gansu University of Traditional Chinese Medicine,Gansu Lanzhou 730000,China;Key Lab of Stem Cells and Gene Drugs of Gansu Province,Gansu Lanzhou 730050,China;Department of Urology,Gansu Provincial People's Hospital,Gansu Lanzhou 730000,China)

机构地区：[1]甘肃中医药大学临床医学院,甘肃兰州730000 [2]甘肃省干细胞与基因药物重点实验室,甘肃兰州730050 [3]甘肃省人民医院泌尿外科,甘肃兰州730000

出　　处：《现代肿瘤医学》2019年第16期2958-2961,共4页Journal of Modern Oncology

基　　金：兰州市人才创新创业项目(编号:2015-RC-16)

摘　　要：前列腺癌多发生于老年男性,其发病率和死亡率正在逐年上升。对于早期前列腺癌,采用阻断雄激素的去势治疗可以有效抑制肿瘤生长,但在治疗2~3年后大部分进展为去势抵抗性前列腺癌,这是导致患者死亡的主要原因。目前,对晚期尤其是去势抵抗性前列腺癌尚缺乏有效的治疗策略,随着生物技术的兴起与发展,针对恶性肿瘤的生物靶向治疗研究日趋深入和成熟,其中慢病毒介导的基因治疗成为研究的热点。运用特异性启动子调控相关基因的表达,可以进一步提高抗肿瘤的靶向性和安全性。本文就目前在基础研究中,前列腺特异性启动子在慢病毒介导下基因靶向治疗前列腺癌的研究现状进行综述。Prostate cancer occurs mostly in older men,and its morbidity and mortality are increasing year by year.For early prostate cancer,castration therapy with blocking androgen can effectively inhibit tumor growth,but most of the progression to castration-resistant prostate cancer after 2 to 3 years of treatment is the main cause of death.At present,there is still no effective treatment strategy for advanced stage,especially castration-resistant prostate cancer.With the rise and development of biotechnology,research on bio-targeted therapy for malignant tumors is becoming more and more mature,including lentivirus-mediated gene therapy which has become a hot spot of research.The use of specific promoters to regulate the expression of related genes can further enhance the anti-tumor targeting and safety.In this paper,the current research status of prostate-specific promoters in lentivirus-mediated gene targeted therapy for prostate cancer is reviewed.

关 键 词：前列腺癌 慢病毒 基因启动子 靶向治疗 基因治疗 

分 类 号：R737.25[医药卫生—肿瘤]